Search results for "CISPLATIN"

showing 10 items of 267 documents

Insights of Tris(2-pyridylmethyl)amine as anti-tumor agent for osteosarcoma: experimental and in silico studies

2021

Abstract Osteosarcoma (OS) is a malignant bone tumor and its occurrence is associated with high levels of microRNAs (miRNAs) and critical protein sinvolved on intracellular signaling pathways. Cisplatin and Doxorubicin are employed on chemotherapy, but their use cause side effects and contributes to multidrug resistance. Since several tripodal amines have been studied as anticancer agents, tris(2-pyridylmethyl)amine (TPA) was investigated against osteosarcoma cells. Here we show that TPA exhibits activity against MG-63 and Saos-2 cells. Cyclic voltammetry results indicate an interaction between TPA and dsDNA, denoted by blocking of the proton-assisted reduction of the 2-pyridylmethyl moiety…

TrisCisplatin010405 organic chemistryChemistryIn silicoOrganic Chemistry010402 general chemistryTris(2-pyridylmethyl)aminemedicine.disease01 natural sciences0104 chemical sciences3. Good healthAnalytical ChemistryInorganic Chemistrychemistry.chemical_compoundmedicineCancer researchOsteosarcoma[CHIM]Chemical SciencesAmine gas treatingDoxorubicinSpectroscopyDNAmedicine.drug
researchProduct

Laparoscopic lymph node dissection should be performed before fertility preserving treatment of patients with cervical cancer

2012

Objective: The aim of this study is to assess our results of treatment of women with stage I cervical cancer > 2 cm in diameter seeking fertility preservation. Treatment consisted of Laparoscopic Pelvic and Paraaortic Lymphadenectomy (LPPLND), and when no nodal metastasis was detected, neoadjuvant chemotherapy (NACT) followed by radical vaginal trachelectomy (RVT). Patients with positive lymph nodes underwent primary chemoradiation. Methods: A cohort of women younger than 40 years of age with stage I disease > 2 cm who underwent LPPLND and either NACT and RVT or chemoradiation. Oncological outcome was evaluated prospectively. Results: Eighteen women were eligible for this study. Twelve (67%…

Uterine Cervical NeoplasmRVTmedicine.medical_treatmentBrachytherapyUterine Cervical NeoplasmsCervix UteriMetastasisParaaortic lymph nodesAntineoplastic Combined Chemotherapy ProtocolsMedicineProspective StudiesFertility preservationProspective cohort studyLymph nodeNeoadjuvant therapyCervical cancerFertility PreservationObstetrics and GynecologyChemoradiotherapyNeoadjuvant Therapymedicine.anatomical_structureOncologyChemotherapy AdjuvantLymphatic MetastasisCarcinoma Squamous CellFemaleRadiologyHumanAdultmedicine.medical_specialtyPaclitaxelPelviRadical vaginal trachelectomyCervical carcinoma; Radical vaginal trachelectomy; Neoadjuvant chemotherapyAdenocarcinomaNeoadjuvant chemotherapyPelvisFollow-Up StudieHumansIfosfamideCervical carcinomaNeoplasm StagingAntineoplastic Combined Chemotherapy Protocolbusiness.industryGeneral surgeryLymphatic Metastasimedicine.diseaseProspective StudieLymph Node ExcisionLaparoscopyCisplatinNeoplasm Recurrence LocalbusinessChemoradiotherapyFollow-Up Studies
researchProduct

Perioperative morbidity and rate of upstaging after laparoscopic staging for patients with locally advanced cervical cancer: results of a prospective…

2015

Objective The International Federation of Gynecology and Obstetrics (FIGO) staging for cervical cancer is based on clinical examination. Previous studies have demonstrated significant upstaging with surgical staging. However, no randomized trial has ever shown a survival benefit when radiation combined with chemoradiation (RCTX) is modified according to surgical staging. The objective of the study was to evaluate the feasibility and outcomes of surgical staging prior to radical RCTX treatment among patients with locally advanced cervical cancer in the setting of a larger, prospective, randomized study (the Uterus-11 study of the German Gynecologic Oncology Group). Study Design Between 2009 …

Uterine Cervical Neoplasmmedicine.medical_treatmentBrachytherapyUterine Cervical NeoplasmsCarcinoma AdenosquamouAntineoplastic AgentPostoperative ComplicationsLaparotomyrandomized triallocally advanced cervical cancerLaparoscopyCervical cancermedicine.diagnostic_testMedicine (all)Lymph NodeObstetrics and GynecologyChemoradiotherapyMiddle Agedlaparoscopic stagingTreatment OutcomeCarcinoma Squamous CellFemaleoperative morbidityHumanAdultmedicine.medical_specialtyPelviBrachytherapyAntineoplastic AgentsGynecologic oncologyAdenocarcinomaPelvisCarcinoma AdenosquamousYoung AdultmedicineHumansExternal beam radiotherapyAgedNeoplasm StagingRadiotherapybusiness.industryPostoperative complicationPerioperativemedicine.diseaseSurgeryFeasibility StudieFeasibility StudiesLymph Node ExcisionLaparoscopyPostoperative ComplicationLymph NodesCisplatinbusinessAmerican journal of obstetrics and gynecology
researchProduct

Synthesis of mesoporous silica nanoparticles (MSNs) and encapsulation of cisplatin for targeted cancer therapies

2014

The aim of this PhD thesis is to elaborate mesoporous silica nanoparticles (MSNs) able to sustain the release of cisplatin into the intracellular compartments of solid tumors. The parametric study shows that morphological, structural and textural properties of MSNs-MCM-41, synthesized by sol-gel reaction by using TEOS as a silica source and CTAB as a structure-directing agent, depend on pH, stirring speed, temperature and extraction process of CTAB. The synthesis atmosphere has to be controlled in order to avoid the presence of ethanol and carbonate species which are responsible of necks between particles generating unstable suspensions of MSNs.MSNs were functionalized in order to control t…

VectorisationCytotoxicityFonctionalizationFonctionnalisationSilicaMesoporousInternalisationStabilitéTensioactifSiliceMésoporeuxCisplatine[SDV.CAN] Life Sciences [q-bio]/Cancer[CHIM.OTHE] Chemical Sciences/OtherCytotoxicitéDrug deliverySurfactantEncapsulationCisplatinStabilityInternalization
researchProduct

Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy

2016

AbstractInactivation of p53 found in more than half of human cancers is often associated with increased tumor resistance to anti-cancer therapy. We have previously shown that overexpression of the phosphatase Wip1 in p53-negative tumors sensitizes them to chemotherapeutic agents, while protecting normal tissues from the side effects of anti-cancer treatment. In this study, we decided to search for kinases that prevent Wip1-mediated sensitization of cancer cells, thereby interfering with efficacy of genotoxic anti-cancer drugs. To this end, we performed a flow cytometry-based screening in order to identify kinases that regulated the levels of γH2AX, which were used as readout. Another criter…

Wip1ApoptosisCell Cycle ProteinsPharmacologyMESH: G2 Phase Cell Cycle CheckpointsHistonesMESH : PhosphorylationMiceMESH : Cell Cycle ProteinsMESH: AnimalsMESH: Tumor Suppressor Protein p53MESH: HistonesKinaseTp53 mutationsMESH : Mice Transgenic3. Good healthProtein Phosphatase 2CSurvival RateMESH : Antineoplastic AgentsH2ax phosphorylationP53 activationMESH: Protein Phosphatase 2CRNA InterferenceMESH : Colorectal NeoplasmsMESH : Carrier ProteinsHistone H2axMESH: MitochondriaImmunologyHuman fibroblastsMESH: Carrier ProteinsAntineoplastic AgentsMESH: Protein-Tyrosine KinasesMESH: Protein-Serine-Threonine KinasesMESH : Cisplatin03 medical and health sciencesMESH: Cell Cycle ProteinsGenotoxic stressMESH : Protein-Tyrosine KinasesHumansMESH : HistonesAnticancer TherapyMESH: DNA DamageCisplatinMESH: HumansMESH: Phosphorylation[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyMESH : HumansMESH : Nuclear Proteins030104 developmental biologyCancer cellMESH: Antineoplastic AgentsCisplatinCarrier ProteinsMESH: Nuclear ProteinsMESH : ApoptosisDna-damage response0301 basic medicineCancer ResearchMESH: Caspase 3MESH : Caspase 3PhosphorylationCytotoxicityMESH : DNA DamageSensitizationmedicine.diagnostic_testCaspase 3Nuclear ProteinsProtein-Tyrosine KinasesMESH : Survival RateMitochondriaG2 Phase Cell Cycle CheckpointsWee1medicine.anatomical_structureMESH : Protein Phosphatase 2COriginal ArticleMESH : MitochondriaColorectal Neoplasmsmedicine.drugMESH : Protein-Serine-Threonine KinasesMESH: Cell Line TumorMESH: Survival RateMESH: Mice TransgenicMESH: RNA InterferencePhosphataseMice Transgenic[SDV.BC]Life Sciences [q-bio]/Cellular BiologyBiologyProtein Serine-Threonine KinasesFlow cytometryCellular and Molecular NeuroscienceCell Line TumorMESH : MicemedicineAnimalsMESH: MiceMESH : Cell Line TumorMESH: ApoptosisCell BiologyMESH : Tumor Suppressor Protein p53MESH: CisplatinCancer researchbiology.proteinMESH : AnimalsMESH : G2 Phase Cell Cycle CheckpointsMESH : RNA InterferenceTumor Suppressor Protein p53MESH: Colorectal NeoplasmsDNA DamageCell Death & Disease
researchProduct

Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients.

2006

Abstract Background: Impaired DNA repair capacity may favorably affect survival in cisplatin/gemcitabine-treated non-small-cell lung cancer (NSCLC) patients. We investigated the association of survival with genetic polymorphisms in X-ray repair cross-complementing group 1 and group 3 (XRCC3), xeroderma pigmentosum group D (XPD), excision repair cross-complementing group 1, ligase IV, ribonucleotide reductase, TP53, cyclooxygenase-2, interleukin-6, peroxisome proliferator-activated receptor γ, epidermal growth factor, methylene-tetra-hydrofolate reductase and methionine synthase. Patients and methods: One hundred and thirty-five stage IV or IIIB (with malignant pleural effusion) NSCLC patien…

Xeroderma pigmentosumLung NeoplasmsDNA RepairGenotypeDeoxycytidineXRCC1Carcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCisplatin; DNA repair genes; Gemcitabine; Non-small-cell lung cancer; Polymorphisms; XRCC3Lung cancerXRCC3Survival analysisCisplatinPolymorphism GeneticDNA repair genesbusiness.industryHazard ratioHematologymedicine.diseaseSurvival AnalysisGemcitabineGemcitabineOncologyCancer researchCisplatinbusinessPolymorphismsNon-small-cell lung cancerNucleotide excision repairmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Efficacy of four cleaning solutions for the decontamination of selected cytotoxic drugs on the different surfaces of an automated compounding system

2018

The automated aseptic preparation of ready-to-administer antineoplastic drug solutions with robotic systems reduces the risk of occupational exposure. However, the surfaces in the preparation area of the robot are to be cleaned by wiping with an appropriate cleaning solution. The aim of the study was to evaluate the cleaning efficacy of four cleaning solutions on four surface materials installed in the APOTECAchemo robot. Predefined amounts of cisplatin (Cis), 5-fluorouracil (5-FU), and cyclophosphamide (CP) were intentionally spread on test plates made of stainless steel, aluminium, polyoxymethylene, and polycarbonate just as installed in the robotic system APOTECAchemo. After drying, the …

business.industryDrug CompoundingAntineoplastic drugDetergentsPublic Health Environmental and Occupational HealthAntineoplastic AgentsRoboticsHuman decontaminationPharmacologyRobotic systemsCompoundingAntineoplastic DrugsMedicineFluorouracilAseptic processingOccupational exposureCisplatinPharmacy Service HospitalbusinessCyclophosphamideDecontaminationJournal of Occupational and Environmental Hygiene
researchProduct

Oxidative Stress and Cognitive Alterations Induced by Cancer Chemotherapy Drugs: A Scoping Review

2021

Cognitive impairment is one of the most deleterious effects of chemotherapy treatment in cancer patients, and this problem sometimes remains even after chemotherapy ends. Common classes of chemotherapy-based regimens such as anthracyclines, taxanes, and platinum derivatives can induce both oxidative stress in the blood and in the brain, and these effects can be reproduced in neuronal and glia cell cultures. In rodent models, both the acute and repeated administration of doxorubicin or adriamycin (anthracyclines) or cisplatin impairs cognitive functions, as shown by their diminished performance in different learning and memory behavioural tasks. Administration of compounds with strong antiox…

cognition0301 basic medicineAntioxidantPhysiologymedicine.medical_treatmentClinical BiochemistryReviewRM1-950Pharmacologymedicine.disease_causeBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMedicine<i>N-</i>acetylcysteineDoxorubicinplatinumCaffeic acid phenethyl esterMolecular BiologyMesnaanthracyclinesCisplatinChemotherapybusiness.industryCancerclinical trialCell Biologymedicine.diseaseN-acetylcysteinetaxanes030104 developmental biologychemistry030220 oncology & carcinogenesisbiomarkerTherapeutics. PharmacologybusinessOxidative stressmedicine.drugAntioxidants
researchProduct

Synergistic Anticancer Therapy by Ovalbumin Encapsulation-Enabled Tandem Reactive Oxygen Species Generation

2020

Abstract The anticancer efficacy of photodynamic therapy (PDT) is limited due to the hypoxic features of solid tumors. We report synergistic PDT/chemotherapy with integrated tandem Fenton reactions mediated by ovalbumin encapsulation for improved in vivo anticancer therapy via an enhanced reactive oxygen species (ROS) generation mechanism. O2 .− produced by the PDT is converted to H2O2 by superoxide dismutase, followed by the transformation of H2O2 to the highly toxic .OH via Fenton reactions by Fe2+ originating from the dissolution of co‐loaded Fe3O4 nanoparticles. The PDT process further facilitates the endosomal/lysosomal escape of the active agents and enhances their intracellular deliv…

inorganic chemicalsNanomedicines | Hot PaperOvalbuminmedicine.medical_treatmentRadicalsynergisticcisplatinPhotodynamic therapyAntineoplastic Agents010402 general chemistry01 natural sciencesCatalysisSuperoxide dismutasechemistry.chemical_compoundMicemedicineAnimalsHumansResearch Articleschemistry.chemical_classificationCisplatinReactive oxygen speciesOxidase testPhotosensitizing Agentsbiology010405 organic chemistryFenton reactionsDrug SynergismGeneral MedicineGeneral ChemistryhypoxicEndocytosis0104 chemical sciencesOvalbuminchemistryphotodynamic therapybiology.proteinBiophysicsMCF-7 CellsReactive Oxygen SpeciesNicotinamide adenine dinucleotide phosphatemedicine.drugResearch Article
researchProduct

Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized …

2008

Summary Purpose A phase III randomized trial was carried out to compare two schedules of the vinorelbine (VNR)–cisplatin (CDDP) regimen in patients with locally advanced unresectable poor prognosis stage IIIB or metastatic stage IV non-small cell lung cancer. The primary endpoints were overall survival (OS) and analysis of toxicity, while secondary endpoints included response rates, time-to-progression (TTP) and quality of life (QoL). Patients and methods Eligible patients were randomized to receive: (a) VNR 25 mg/m 2 on day 1, 8 and 15 plus CDDP 100 mg/m 2 on day 1 every 4 weeks or (b) VNR 30 mg/m 2 on day 1 and 8 plus CDDP 80 mg/m 2 on day 1 every 3 weeks. All patients were chemotherapy-n…

inorganic chemicalsPulmonary and Respiratory MedicineAdultMaleCancer Researchmedicine.medical_specialtyRandomizationLung NeoplasmsVinorelbineVinblastineGastroenterologyStatistics Nonparametriclaw.inventionRandomized controlled triallawInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesLung cancerProspective cohort studyneoplasmsAgedNeoplasm StagingChi-Square Distributionbusiness.industryVinorelbineMiddle Agedmedicine.diseaseVinblastineSurgeryRegimenLogistic ModelsTreatment OutcomeOncologyItalyDisease ProgressionQuality of LifeFemaleCisplatinbusinessFebrile neutropeniamedicine.drugLung cancer (Amsterdam, Netherlands)
researchProduct